Drug Profile
Research programme: RNAi therapeutics - Alnylam Pharmaceuticals/Regeneron Pharmaceuticals
Alternative Names: RNAi therapeutics - Regeneron Pharmaceuticals/Alnylam PharmaceuticalsLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
- Class Gene therapies; Ribonucleosides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glaucoma
- No development reported CNS disorders; Eye disorders; Liver disorders
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in CNS-disorders in USA (Parenteral)
- 28 May 2023 No recent reports of development identified for preclinical development in Eye-disorders in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for research development in Liver-disorders in USA (Parenteral)